Tensys Medical T-Line ICU Experience Published in British Journal of Anesthesia

SAN DIEGO --(Business Wire)--

Tensys Medical, Inc., a leader in the development and commercialization of continuous, non-invasive hemodynamic patient monitoring systems, announced that a scientific paper evaluating the use of the company's T-line technology has been published in the British Journal of Anesthesia (03/13/13-advance online publication). In this study, the investigators compared blood pressure measurements in 34 medical ICU patients using the TL-200pro non-invasive method versus invasive femoral artery catheterization. The authors reported that the TL-200pro system is able to provide mean arterial pressure (MAP) values with high accuracy and precision when compared to invasively assessed MAP values. According to Dr. Bernd Saugel, lead author of the paper, "The emerging role of non-invasive technologies in the monitoring of critically ill patients is clear, and the TL-200pro is a promising candidate for both patients and physicians when compared to traditional, invasive approaches."

The TL-200Pro is a member of the T-Line family which has successfully been used by over 50,000 patients since commercial launch. The technology accurately and continuously captures a patient's beat-to-beat waveform and blood pressure in a completely non-invasive fashion, providing physicians with a stream of real-time hemodynamic data that is not possible using traditional non-invasive blood pressure (cuff) devices. Avoiding the blind-time associated with a deflated or inaccurate cuff can enhance hemodynamic monitoring, which has been definitively linked toimproved clinical outcomes. Today, the T-line family is used in a number of clinical environments including the operating room, intensive care unit (ICU), and electrophysiology lab.

"This paper highlights the versatility of the T-line technology. Beyond the system's traditional position in the operating room marketplace, the authors have demonstrated the increasing role the device can play in the monitoring of very complex medical ICU patients," commented Dr. Oliver Goedje, Tensys' Medical Director. "The impact of non-invasive monitoring in the ICU will be even more pronounced as we will soon add the ability to monitor cardiac output and additional hemodynamic parameters using our recently 510(k) cleared, next generation TL-300 platform."

Tensys management will be providing additional details regarding this data and launch of its next generation products as the company exhibits at the upcoming 2013 International Symposium on Intensive Care and Emergency Medicine (03/19/13-03/22/13, Brussels, Belgium). For additional details, please visit www.tensysmedical.com and/or contact Dr. Eric Daniels, Vice President, Marketing & Sales, Tensys Medical (edaniels@tensysmedical.com)

About Tensys

Tensys Medical, Inc. is a leader in the development and commercialization of continuous, non-invasive, hemodynamic monitoring systems. Without a single needle stick, the company's FDA approved and CE-Marked T-line technology is used today in hospital operating rooms, ICUs and electrophysiology labs to provide a patient's real-time pulse pressure waveform and blood pressure. With the future addition of advanced hemodynamic parameters, Tensys is positioned to continue its leadership in the growing, non-invasive, hemodynamic marketplace.

Cautionary Statement Regarding Forward-Looking Statements

This press release may include "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as "will," "near future," "positioned," "provide," or other words or phrases of similar import that are intended to identify forward-looking statements. Similarly, statements herein that describe Tensys Medical's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements, including: the clinical and commercial potential and success of the company's TL-300 product and T-Line product line; general economic and business conditions; and other risks and important factors that could cause actual results to differ materially from the forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this announcement, and Tensys Medical undertakes no obligation to update the forward-looking statements to reflect subsequent events or circumstances after the date on which they were made.